Abstract. New therapeutic approaches are mandatory for anaplastic thyroid cancer. We investigated the ability of a new combined treatment using valproic acid (VPA), the only clinically available histone deacetylase inhibitor, and the tyrosine-kinase inhibitor imatinib mesylate to control the cell growth of anaplastic thyroid cancer cell lines. We showed that treatment with imatinib alone is unable to affect the cell growth of anaplastic thyroid cancer cells, whereas in ARO cells, the combined treatment resulted in a cytostatic effect, with clinically achievable doses of imatinib and VPA. The effect is mediated by G 1 growth arrest, acting through p21 expression and the impairment of AKT phosphorylation.
Introduction
Anaplastic thyroid cancer (ATC) is one of the most aggressive malignancies in humans. Multi-disciplinary treatments including radio-and chemotherapy poorly control the progression of this disease and patients rarely survive >1 year after initial diagnosis (1) . Novel strategies to control this lethal malignancy are therefore mandatory (2, 3) . Imatinib mesylate is a molecular target agent that suppresses signal transduction pathways mediated through c-Abl, c-kit, and platelet-derived growth factor receptors (PDGFRs) (4) . Imatinib is already used to treat patients with chronic myeloid leukaemia (CML) over-expressing Bcr-Abl mutant proteins (5) and those with gastrointestinal stromal tumours (GIST) harboring active forms of c-kit somatic mutations (6) . Moreover, preclinical studies suggested a potential antitumour activity of imatinib in other solid tumours, such as ovarian cancer (7), prostate cancer (8) , neuroblastoma (9) and osteosarcoma (10) . Only a few reports on the effect of imatinib on ATC cells are currently available, with contradictory results (11) (12) (13) . Podtchecko et al (11) demonstrated that imatinib is a potential anticancer drug against undifferentiated thyroid carcinoma. However, achieving the necessary doses of imatinib which would have cytotoxic effects on ATC cells in patients is difficult. Moreover, even if the doses were achieved by higher dosing, it would result in dose-limiting toxicity (12) . Thus, imatinib mesylate monotherapy appears to be ineffective in suppressing human ATC cell growth in vitro.
Reinforcement of the killing activity of drugs targeting DNA (2, 14, 15) and tubulin (3) has been reported for histone deacetylase inhibitors (HDIs), a potent class of antineoplastic agents. These drugs induce differentiation, growth arrest and apoptosis of transformed cells (16) (17) (18) . Several HDIs such as SAHA (19) , LAQ824 (20) , MS-275 (21) and valproic acid (22) enhance imatinib-induced growth arrest and apoptosis in imatinib-sensitive and -resistant leukaemic cell lines.
We investigated the ability and underlying mechanisms of a new combined treatment using valproic acid (VPA), the only clinically available HDI, and imatinib mesylate to regulate the cell growth of ATC cell lines.
Materials and methods
Drugs, cell lines and culture conditions. Valproic acid was purchased from Sigma-Aldrich and imatinib mesylate was kindly provided by Novartis Pharma AG (Basel, Switzerland).
Anaplastic thyroid carcinoma cell lines (CAL-62 and 8305C) were purchased from the Deutche Sammlung von Mikroorganismen and Zellculturen (Braunschweig, Germany), while ARO cells were a kind gift from Professor Paola Cassoni (Pathology Service, Department of Oncology, University of Turin). CAL-62 cells were routinely maintained in DMEM-F12 (Invitrogen, Groningen, The Netherlands) supplemented with 10% heat-inactivated FCS (Euroclone, Wetherby, West York, UK). 8305C cells were maintained in Eagle's essential minimal medium (E-MEM) supplemented with 1% non-essential amino acids (Sigma) and 10% heat-inactivated FCS. The ARO cell line was maintained in RPMI-1640 (Sigma, St. Louis, MO, USA) supplemented with 10% heat-inactivated FCS.
Cell viability and cytotoxicity. To assess the effect of VPA on imatinib antitumour activity, cells were seeded at 1x10 3 /well in 96-well plates (Corning, New York, NY, USA) in culture medium added with 10% heat-inactivated FCS. After 48 h, cells were exposed to 0.7 mM VPA for 24 h before the addition of imatinib (1-10 μM). After a further 72-h incubation, cell viability was tested using the Cell Proliferation Reagent WST-1 (Roche Applied Science, Penzberg, Germany), following the manufacturer's instructions. Four replicate wells were used to determine each data point. Three response parameters were calculated for each cell line: the median growth inhibition (GI 50 ), total growth inhibition (TGI) and median lethal concentration (LC 50 ). GI 50 defines the concentration of the compound that inhibits 50% net cell growth, the TGI value is the concentration leading to total inhibition and LC 50 is the lethal dose of the drug for 50% net of cells. The dose of 0.7 mM VPA has been selected because it corresponds to plasma levels in patients treated for epilepsy.
Concerning imatinib doses, the higher concentration used in our study (10 μM) is just beyond the mean plasma concentration (7.8 μM) reached in CML patients treated with 600 mg of imatinib once daily in a phase II clinical study (23) .
Apoptosis detection
Cell death detection ELISA. For apoptosis studies, 1x10 3 cells/well were seeded in 96-well plates and treated with VPA and imatinib (5 and 8 μM), using the same schedule as for the antitumour activity. After different treatments, apoptosis was evaluated using cell death detection ELISA Plus (Roche Applied Science) following the manufacturer's instructions. Apoptosis was expressed as an enrichment factor, and calculated as a fraction of the absorbance of treated cells versus untreated controls.
Caspase activity assay. Cells (5x10 5 ) were seeded in 75 cm 2 flasks and exposed to VPA and imatinib as above. After drug treatments, caspase 3 was determined using a colorimetric assay kit (R&D Systems Inc., Minneapolis, MN, USA). Briefly, cells were lysed and incubated with the colorimetric substrate DEVD-pNA for 2 h at 37˚C. After incubation, the chromophore was quantified spectrophotometrically at 405 nm.
Cell cycle analysis. Cells were treated with 0.7 mM VPA for 24 h, followed by treatment with 5 or 8 μM imatinib for 48 h.
After treatment, cells were collected, fixed in 70% ethanol for 30 min on ice and incubated in propidium iodide solution (20 μg/ml propidium iodide and 0.2 mg/ml RNAseA in PBS) for 1 h at room temperature. The cell population was analyzed by flow cytometry.
Gene expression evaluation with real-time PCR
RNA extraction. Cells (2x10 5 /well) were seeded in 6-well plates and treated as described above. Total RNA was extracted using TRIzol reagent (Invitrogen Ltd., Paisley, UK). DNase was added to remove genomic DNA residuals.
cDNA synthesis and PCR amplification for Abl, c-kit, PDGFR-ß, AKT, p21 and p27. Total RNA (1 μg) was reversetranscribed with iScript cDNA synthesis kit (BioRad Laboratories, Inc.), following the manufacturer's protocol.
Primers were designed using Beacon Designer 5.0 software according to parameters outlined in the BioRad iCycler manual. Primer specificity was confirmed by BLAST analysis. The primer sequences are listed in Table I . Actin, ß2-microglobulin and ribosomal protein L13a were used as housekeeping genes.
Real-time PCR was performed using the BioRad iQ iCycler detection system (BioRad Laboratories, Inc.) with SYBR-Green as a fluorophore. The total reaction volume was 25 μl and included 12.5 μl iQ SYBR-Green Supermix (BioRad Laboratories, Inc.), 1 μl of 10 μM primer and 5 μl of previously reverse-transcribed cDNA template. Conditions of RT-PCR included denaturation at 95˚C for 5 min and 40 cycles of amplification (95˚C for 15 sec and 60˚C for 30 sec). A melt curve analysis was performed following every run to ensure a single product of amplification for every reaction. Reactions were carried out at least in triplicate for each sample. Relative expression levels were obtained using the GeneEx program (BioRad), after geometrical normalization against the three different housekeeping genes.
Western blot analysis. Cells (1x10 6 ) were seeded in 75 cm 2 flasks and treated as described for cell cycle analysis. After treatment, the cells were lysed in RIPA buffer (PBS, pH 7.4, 1% Nonidet P40, 0.1% SDS and 0.5% sodium deoxycholate) added with 100 μg/ml PMSF, 30 μl/ml aprotinin, 100 mM NaVO 4 and 0.7 VPA when required to maintain acetylation. The cells were extracted at 4˚C for 30 min and centrifuged at Table I . Primer sequences for real-time PCR.
for 20 min at 15,000 x g. Aliquots of 50 μg of total protein were loaded to each lane of 12% (for p21 and actin) or 8% (for Akt and P-Akt) SDS-polyacrylamide gels and proteins were electrically transferred to PVDF membranes. Membranes were probed with the primary antibodies of polyclonal antip21 (sc-397, 1:200 dilution, Santa Cruz Biotechnology Inc., Santa Cruz, CA, USA); monoclonal anti-actin (clone AC-40, 1:1000 dilution, Sigma); polyclonal anti-phospo-Akt (Ser473; 1:1000 dilution, Cell Signaling Technology Inc., Danvers, MA, USA) and polyclonal anti-Akt (1:2000 dilution, Cell Signaling Technology Inc.). The secondary antibodies were diluted at 1:10000. Western blot analysis against actin was used to control protein loading.
Proteins were detected with the Pierce Super Signal chemiluminescent substrate following the manufacturer's instructions. Bands were photographed using the PC software 1D Kodak Digital Science.
Statistical analysis. Data are expressed throughout as means ± SEM, calculated from at least three different experiments.
In viability experiments, the statistical comparison between cells treated with VPA plus imatinib, and VPA alone was performed with the Mann-Whitney U test. A comparison between the groups was performed with analysis of variance (one-way ANOVA) and the threshold of significance was calculated with the Bonferroni test. Statistical significance was set at P<0.05.
Results
Effect of VPA and imatinib on cell viability. As shown in Fig. 1 and Table II , treatment with imatinib alone up to the dose of 10 μM had no effect on the growth of ATC cell lines (CAL-62, ARO and 8305C). Pre-treatment with 0.7 mM VPA significantly increased the imatinib effect in ARO cells (P<0.05), whereas no potentiation was observed in CAL-62 and 8305C cells.
Effect of VPA and imatinib on cell cycle progression and apoptosis induction. To get insight into the mechanisms underlying the antitumour effect of the combined treatment with VPA and imatinib in ARO cells, we evaluated the effect of the two drugs on cell cycle progression and apoptosis induction. As shown in Table III , neither VPA nor imatinib (up to the dose of 8 μM) had any effect on cell cycle progression (Table III) and apoptosis induction (Fig. 2) of ATC cells, when used alone. Pre-treatment with VPA resulted in G 1 cell cycle arrest in ARO cells, a total of 58.8% of VPA + 5 μM imatinib-treated cells were in G 1 compared with 48.1% of cells cultured with 5 μM imatinib alone (p<0.01) and a total of 66.0% of VPA + 8 μM imatinibtreated cells were in G 1 compared with 58.8% of cells cultured with 8 μM imatinib alone (p<0.001).
After combined treatment, we observed no apoptosis induction at any concentration used, nor were nucloeosome Table II . GI 50 , TGI and LC 50 for imatinib (μM) after treatment with imatinib alone or combined with VPA. GI 50  ≥10  ≥10  ≥10  5  ≥10  ≥10  TGI  ≥10  ≥10  ≥10  ≥10  ≥10  ≥10  LC 50  ≥10  ≥10  ≥10  ≥10  ≥10  ≥10  - --------------------------------------------------------------------------------------------------- -Table III . Effect of VPA and imatinib on cell cycle progression of ATC cell lines. formation (Fig. 2 ) and caspase activation (data not shown) detected.
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Effect of VPA and imatinib on p21 and p27 gene expression.
To clarify the mechanism of VPA plus imatinib-induced G 1 cell cycle arrest in ARO cells, we examined the effect of the drugs on p21 and p27 gene expression involved in cell cycle control. p21 was up-regulated at the mRNA (Fig. 3A) and protein levels (Fig. 3B) . Conversely, the mRNA expression of p27 was not changed upon treatment (Fig. 3A) .
Effect of VPA and imatinib on the expression of c-Abl, c-kit, PDGFR and AKT.
Neither c-kit nor PDGFR were expressed in any of the cells (data not shown). c-Abl mRNA expression was observed in the ATC cell lines used for the study. Notably, in ARO cells the expression was only one third versus CAL-62 and 8305C cells. VPA plus imatinib treatment had no effect on the modulation of the gene expression (Fig. 4) . Regarding AKT expression in ARO cells, drug treatments determined the inhibition of AKT phosphorylation, without any effect on the amount of total AKT (Fig. 5B ) and on the mRNA expression level (Fig. 5A) . No modulation of AKT expression and phosphorylation was observed in either CAL-62 or 8305C cells (data not shown).
Discussion
In the present study, we showed that treatment with imatinib alone is unable to affect the cell growth of anaplastic thyroid cancer cells, which is in line with previous data by Dziba et al (12) . Other authors (11) have previously reported that only cell lines harbouring mutated p53 are sensitive to the drug. However, although the cell lines used in this study are p53-mutated, they are resistant to imatinib when used alone up to the dose of 10 μM.
We demonstrated that a combined treatment of valproic acid and imatinib at concentrations clinically achievable for the two drugs, affects cell viability of the ARO cells, where a cytostatic effect is observed. The underlying mechanism is cell cycle arrest in G 1 , whereas no apoptosis induction is observable. Cell cycle arrest is the result of the activation of p21 expression. HDIs induce cell-cycle arrest at G 1 /S (24) and this is most often associated with the p53-independent induction of CDKN1A, encoding p21. We demonstrated elsewhere (25) that VPA is able to induce p21 expression in poorly differentiated thyroid cancer cell lines, but no induction was observed when the drug was administered alone in anaplastic thyroid cancer cells.
The tyrosine kinase inhibitor imatinib selectively suppresses the activity of Abl, PDGFR and c-kit. In our cell lines, PDGFR and c-kit are not expressed and neither the drugs used alone nor the combined treatment are able to induce their expression. In contrast, RT-PCR revealed the presence of c-Abl mRNA in the cell lines we used. Abl affects cell proliferation phosphorylating many targets, including AKT (26) . AKT regulates the process of cell survival by multiple substrates including cyclin D, Myc, p27 and p21 (27) . In detail, AKT phosphorylates the cell cycle inhibitor p21 at two different residues, resulting in the cytoplasmatic localization of p21 and consequent promotion of the cell cycle (28) . We showed that treatment with imatinib and valproic acid inhibits AKT phosphorylation. The question remains as to why valproic acid potentiates the action of imatinib only in ARO cells that express a lower level of Abl. Abl expression in ARO cells is one third lower than in CAL-62 and 8305C cells. VPA (22) mRNA levels were determined with real-time PCR and normalized against actin, ß2-microglobulin and protein L13a. Results are expressed as fold induction compared to the untreated control group. Phosphorylated AKT protein was analyzed by Western blot analyis. pAKT levels were determined using an antibody against phosporylated AKT. Equal loading and transfer were verified by reprobing the membranes with an anti-AKT antibody.
been reported to decrease the mRNA and protein levels of Bcr-Abl in myeloid leukaemia cells, enhancing imatinibinduced growth arrest. However, to our knowledge, the different treatments are not able to modify the expression of Abl in any of the cell lines. We suggest that valproic acid acts downstream of Abl expression, directly working against the phosphorylation of AKT induced by Abl. The lack of effects on the other cell lines may be dependent, at least partially, on the overexpression of Abl. In this case, the phosphorylating activity of Abl on AKT may overwhelm the inhibitory effect of the combined treatment.
Therefore, cell cycle arrest observed in ARO cells after treatment with imatinib and valproic acid is the result of the induction of p21 expression and inhibition of AKT phosphorylation. p21 is a well-known cell cycle inihibitor and AKT phosphorylation in turn regulates the G 1 /S transition by controlling the cell cycle inhibitor p21 at the post-translational level. AKT phosphorylates p21 at the residues Thr145 and Ser146. Thr145 residue phosphorylation results in the cytoplasmatic localization of p21 promoting the cell cycle, whereas Ser146 site phosphorylation enhances the stability of the protein and increases the assembly of the cyclin D-CDK4 transition complex.
VPA was shown to able to interfere with the AKT pathway, together with its ability to potentiate the activity of other anti-neoplastic agents with different mechanisms (2,3) which defines the multifaceted activities of this sole clinically available HDI.
In conclusion, although a phase II clinical trial (Clinical Trials.gov Identifier: NCT00115739) using imatinib for the treatment of anaplastic thyroid cancer continues, the data from our investigations appear to discourage the monotherapeutic use of imatinib in this type of tumour. A combined treatment with imatinib and an HDI inhibitor such as valproic acid may be more effective. However, such treatment should be assessed in each case, as we observed the anti-tumour activity in only a single cell line.
